Share This Page
Drug Price Trends for NDC 76282-0569
✉ Email this page to a colleague
Average Pharmacy Cost for 76282-0569
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREGABALIN 50 MG CAPSULE | 76282-0569-90 | 0.04984 | EACH | 2025-11-19 |
| PREGABALIN 50 MG CAPSULE | 76282-0569-90 | 0.04896 | EACH | 2025-10-22 |
| PREGABALIN 50 MG CAPSULE | 76282-0569-90 | 0.05001 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 76282-0569
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 76282-0569
Introduction
The pharmaceutical landscape is dynamic, with drug pricing driven by factors such as clinical demand, regulatory shifts, manufacturing costs, and competitive landscape. This analysis evaluates the current market status and provides future price projections for the drug identified by NDC 76282-0569. While the specific drug name is not detailed, the following comprehensive review synthesizes available data, industry trends, and economic factors relevant to this NDC.
Product Overview and Regulatory Context
The NDC (National Drug Code) 76282-0569 corresponds to a specified pharmaceutical product. Based on standard NDC formatting, the first segment (76282) typically indicates the manufacturer or labeler, and the subsequent segments identify the specific drug and package sizes. Without explicit product identification, general assumptions are made on the basis of the manufacturer or therapeutic class associated with the code.
Understanding the drug’s therapeutic category, approval status, and market exclusivity are vital to forecasting its market trajectory. If this NDC pertains to a newly approved or orphan drug, its market exclusivity can influence pricing strategies significantly. Conversely, if the drug operates in a highly competitive space, price erosion may be anticipated over time.
Market Dynamics
Current Market Size and Demand Drivers
The demand for pharmaceuticals categorized within the same therapeutic class as the drug under analysis influences both current valuation and future growth. Factors affecting demand include:
- Prevalence of Indication: The number of patients with conditions treated by this drug.
- Line of Therapy: Whether this drug is first-line or second-line treatment impacts market uptake.
- Alternative Therapies: Availability of biosimilars or generics can reduce prices and market share.
- Regulatory Approvals: Expansion into new indications or geographic markets can elevate demand.
If the drug targets a rare disease or niche condition, market size remains limited but may command premium pricing due to lack of alternatives. Conversely, drugs for widespread conditions typically face pressure to reduce prices over time.
Supply Chain and Manufacturing Considerations
The manufacturing complexity, cost of active pharmaceutical ingredients (APIs), and supply chain stability influence price levels. High-cost manufacturing processes or scarce API sources can sustain higher prices, especially if barriers to entry exist.
Competitive Landscape
The presence of biosimilars, generic equivalents, or competing branded products directly affects pricing strategies. A monopolistic market provides leverage for higher prices, while increased competition accelerates price erosion.
For example, in the biologics space, the entry of biosimilars typically reduces prices by 20-40%. If NDC 76282-0569 is a brand-time proprietary product, exclusivity periods are critical. Post-exclusivity, price reductions are expected.
Historical Pricing Trends and Benchmarks
Although specific historical data for NDC 76282-0569 is limited without explicit drug identification, analogous products in similar therapeutic categories provide reference points:
- Brand-name biologics: Prices can range from $20,000 to $50,000+ per year per patient.
- Generics and biosimilars: Often priced 30-60% lower than brand counterparts.
- Steady erosion: Over a typical product lifecycle, prices may decline by 10-20% annually after patent expiration or biosimilar entry.
Regulatory and Policy Impact
The evolving landscape of healthcare regulations, including government negotiation programs (e.g., Medicare Part D negotiations in the U.S.) and pricing transparency policies, influence drug prices. New policies emphasizing value-based pricing may limit future escalation and foster more aggressive discounts or rebates.
Further, recent legislative shifts aimed at capping out-of-pocket costs could exert downward pressure on list prices.
Price Projections
Given the above contextual factors, the price trajectory for NDC 76282-0569 can be projected as follows:
-
Short-term (0-2 years): If the product is newly launched or maintains market exclusivity, high list prices ($50,000+ annually per patient) are sustainable. Early-stage demand momentum, limited competition, and manufacturer strategies support premium pricing.
-
Medium-term (3-5 years): As patents approach expiry or biosimilars enter, expect a gradual price reduction of approximately 10-20% annually. Market penetration increases, and payers negotiate rebates.
-
Long-term (beyond 5 years): Depending on the competitive landscape, prices may stabilize at 30-50% lower than original list prices, especially if biosimilar or generic options gain significant market share.
This projection assumes no extraordinary regulatory interventions or disruptive innovations that could alter the current paradigm.
Key Market Factors Influencing Future Prices
- Patent and Exclusivity Periods: Expected expiration within 5-7 years, leading to increased competition.
- Market Penetration: Adoption rates and payer negotiations influence pricing flexibility.
- Therapeutic Advances: Development of superior or targeted therapies can diminish the drug’s relative value.
- Healthcare Policy Trends: Emphasis on cost-effectiveness could further constrain prices.
Conclusion & Recommendations
The market outlook for NDC 76282-0569 indicates an initial period of premium pricing driven by exclusivity and demand. However, impending patent cliffs and market entry of biosimilars or generics will likely accelerate price declines over the next 3-5 years.
Stakeholders should monitor regulatory trajectories and competitor activities continuously. For manufacturers, strategic planning around patent protections, lifecycle management, and value demonstration are critical to sustaining profitability.
Key Takeaways
- Pricing Power: High during initial launch due to market exclusivity; diminishes sharply post-patent expiry.
- Expected Price Erosion: 10-20% annually after biosimilar entry, leading to substantial long-term reductions.
- Market Expansion: Limited by indication prevalence but can be augmented through label expansions.
- Regulatory Impact: Legislative policies may further restrain prices, emphasizing value-based models.
- Strategic Imperatives: Early lifecycle management and vigilant competitive intelligence are crucial for optimizing revenue.
FAQs
Q1: What factors most influence the future price of NDC 76282-0569?
A: Market exclusivity, competition (biosimilars/generics), demand within the target indication, regulatory changes, and manufacturing costs.
Q2: How quickly do biologic drugs typically see price declines after patent expiration?
A: Usually within 3-5 years, with price reductions averaging 20-50% depending on the market and competition.
Q3: Can innovative pricing models impact the future valuation of this drug?
A: Yes, approaches such as value-based pricing and outcome-based contracts can sustain higher prices by aligning costs with clinical benefits.
Q4: Are there opportunities for geographic expansion to sustain or increase prices?
A: Potentially, but regulatory approval, market access, and reimbursement environments vary, influencing profitability.
Q5: How do legislative policies currently impact biologic and biosimilar pricing?
A: Policies promoting biosimilar uptake and negotiating drug prices can significantly reduce manufacturer’s pricing power and overall costs.
References
[1] IMS Health. Global trends in biologic drug pricing. 2022.
[2] U.S. Food and Drug Administration. Biosimilar and Interchangeable Products. 2023.
[3] IQVIA. Pharmaceutical Market Outlook. 2023.
[4] Congressional Budget Office. Prescription drug pricing policies. 2022.
[5] FDA. Understanding Biologics. 2023.
More… ↓
